Cargando…

mRNA Vaccines Enhance Neutralizing Immunity against SARS-CoV-2 Variants in Convalescent and ChAdOx1-Primed Subjects

To identify the most efficient methods of immunological protection against SARS-CoV-2, including the currently most widespread variants of concern (VOCs)—B.1.1.7, B.1.351 and P.1—a simultaneous side-by-side-comparison of available vaccination regimes is required. In this observational cohort study,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fabricius, Dorit, Ludwig, Carolin, Scholz, Judith, Rode, Immanuel, Tsamadou, Chrysanthi, Jacobsen, Eva-Maria, Winkelmann, Martina, Grempels, Aline, Lotfi, Ramin, Janda, Aleš, Körper, Sixten, Adler, Guido, Debatin, Klaus-Michael, Schrezenmeier, Hubert, Jahrsdörfer, Bernd
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8402682/ https://www.ncbi.nlm.nih.gov/pubmed/34452043 http://dx.doi.org/10.3390/vaccines9080918

Ejemplares similares

BNT162b2 Vaccination Elicits Strong Serological Immune Responses Against SARS-CoV-2 Including Variants of Concern in Elderly Convalescents
por: Jahrsdörfer, Bernd, et al.
Publicado: (2021)

BNT162b2 Booster Vaccination Elicits Cross-Reactive Immunity Against SARS-CoV-2 Variants B.1.1.529 and B.1.617.2 in Convalescents of All Ages
por: Jahrsdörfer, Bernd, et al.
Publicado: (2022)

Differentially induced immunity in buccal and nasal mucosae after vaccination for SARS–CoV–2: Prospects for mass scale immunity-screening in large populations
por: Tsamadou, Chrysanthi, et al.
Publicado: (2022)

SARS-CoV-2 vaccination of convalescents boosts neutralization capacity against Omicron subvariants BA.1, BA.2 and BA.5 and can be predicted by anti-S antibody concentrations in serological assays
por: Seidel, Alina, et al.
Publicado: (2023)

Erytra blood group analyser and kode technology testing of SARS‐CoV‐2 antibodies among convalescent patients and vaccinated individuals
por: Weinstock, Christof, et al.
Publicado: (2021)

Cytokine levels associated with favorable clinical outcome in the CAPSID randomized trial of convalescent plasma in patients with severe COVID-19
por: Körper, Sixten, et al.
Publicado: (2022)

Donors for SARS-CoV-2 Convalescent Plasma for a Controlled Clinical Trial: Donor Characteristics, Content and Time Course of SARS-CoV-2 Neutralizing Antibodies
por: Körper, Sixten, et al.
Publicado: (2021)

Phorbol-12-myristate-13-acetate is a potent enhancer of B cells with a granzyme B(+) regulatory phenotype
por: Veh, Johanna, et al.
Publicado: (2023)

One-year follow-up of the CAPSID randomized trial for high-dose convalescent plasma in severe COVID-19 patients
por: Körper, Sixten, et al.
Publicado: (2022)

Stability of Chimpanzee Adenovirus Vectored Vaccines (ChAdOx1 and ChAdOx2) in Liquid and Lyophilised Formulations
por: Berg, Adam, et al.
Publicado: (2021)

Lyophilization to enable distribution of ChAdOx1 and ChAdOx2 adenovirus-vectored vaccines without refrigeration
por: Zhang, Cheng, et al.
Publicado: (2023)

ATP promotes immunosuppressive capacities of mesenchymal stromal cells by enhancing the expression of indoleamine dioxygenase
por: Lotfi, Ramin, et al.
Publicado: (2018)

Early, very high-titre convalescent plasma therapy in clinically vulnerable individuals with mild COVID-19 (COVIC-19): protocol for a randomised, open-label trial
por: Desmarets, Maxime, et al.
Publicado: (2023)

Inflammatory myositis after ChAdOx1 vaccination
por: Maramattom, Boby Varkey, et al.
Publicado: (2021)

ChAdOx1-S vaccine for prevention of COVID-19
Publicado: (2021)

New Trends in Hemapheresis
por: Worel, Nina, et al.
Publicado: (2023)

Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2
por: Hermosilla, Eduardo, et al.
Publicado: (2022)

Pulmonary Function and Persistent Clinical Symptoms in Children and Their Parents 12 Months After Mild SARS-CoV-2 Infection
por: Bode, Sebastian F. N., et al.
Publicado: (2022)

Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants
por: Groß, Rüdiger, et al.
Publicado: (2021)

Postvaccinal Encephalitis after ChAdOx1 nCov‐19
por: Zuhorn, Frédéric, et al.
Publicado: (2021)

The COVID‐19 vaccine ChAdOx1‐S is not contaminated with sulfated glycosaminoglycans
por: Alban, Susanne, et al.
Publicado: (2022)

Prolonged febrile illness following first dose of ChAdOx1
por: Caruana Dingli, Michael, et al.
Publicado: (2023)

Depression following ChAdOx1-S/nCoV-19 vaccine
por: Uvais, N.A.
Publicado: (2022)

Thromboses of major arteries and ChAdOx1 nCov-19 vaccination
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2021)

Chronic spontaneous urticaria following ChAdOx1-S COVID-19 vaccination
por: Suan, Dan, et al.
Publicado: (2022)

Myelin Oligodendrocyte Glycoprotein-Associated Disorders Post-ChAdOx1 Vaccination
por: Maramattom, Boby Varkey
Publicado: (2022)

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination
por: Greinacher, Andreas, et al.
Publicado: (2021)

Delayed large local reaction to the adenovirus-vectored (ChAdOx1) vaccine
por: Grobusch, Martin P., et al.
Publicado: (2021)

Central nervous system adverse events after ChAdOx1 vaccination
por: Maramattom, Boby Varkey, et al.
Publicado: (2022)

De novo psoriasis induced by ChAdOx1-S COVID 19 vaccine()
por: Zaiem, Ahmed, et al.
Publicado: (2022)

Population-wide persistent hemostatic changes after vaccination with ChAdOx1-S
por: de Laat, Bas, et al.
Publicado: (2022)

Altered increase in STAT1 expression and phosphorylation in severe COVID‐19
por: Rincon‐Arevalo, Hector, et al.
Publicado: (2021)

Serum neutralizing capacity and T-cell response against the omicron BA.1 variant in seropositive children and their parents one year after SARS-CoV-2 infection
por: Seidel, Alina, et al.
Publicado: (2023)

Evaluation of Two-Month Antibody Levels after Heterologous ChAdOx1-S/BNT162b2 Vaccination Compared to Homologous ChAdOx1-S or BNT162b2 Vaccination
por: Barocci, Simone, et al.
Publicado: (2022)

Immune complexes, innate immunity, and NETosis in ChAdOx1 vaccine-induced thrombocytopenia
por: Holm, Sverre, et al.
Publicado: (2021)

Polyarthralgia and Myalgia Syndrome after ChAdOx1 nCOV-19 Vaccination
por: Hyun, Hakjun, et al.
Publicado: (2021)

Portal vein thrombosis associated with ChAdOx1 nCov-19 vaccination
por: Öcal, Osman, et al.
Publicado: (2021)

Autoimmune encephalitis following ChAdOx1-S SARS-CoV-2 vaccination
por: Kwon, Hyeryung, et al.
Publicado: (2021)

Reversible radiculomyelitis after ChAdOx1 nCoV-19 vaccination
por: Spataro, Rossella, et al.
Publicado: (2022)

Two flares of Still’s disease after two doses of the ChAdOx1 vaccine
por: Roongta, Rashmi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_07rbrlh1c8omabp1icq7dgiehc